USA buys 500 million vaccine doses for lower-income countries

10 June 2021

The US government has committed to buying 500 million doses of BNT162b2/Comirnaty, the vaccine provided by Pfizer (NYSE: PFE) and BioNTech (Nasdaq: BNTX), for lower-income countries.

US President Joe Biden is expected to formally announce the plan while the G7 meeting of rich democracies is taking place in Carbis Bay, UK.

The drugmakers have said they will supply the vaccines at a not-for-profit price, with 200 million doses to be delivered in 2021 and 300 million doses in the first half of 2022.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK